The patients with advanced (stage III, IV) endometrial cancer remain a substantial number with adverse prognostic features who relapse and die of this disease. Recently, the feasibility of administering the combination of chemotherapy and radiotherapy has been reported in the setting of advanced endometrial cancer with the impressive outcome. Sequential therapy consisted of paclitaxel and carboplatin for 3 cycles, followed by pelvic and/or para-aortic radiotherapy and an additional 3 cycles of chemotherapy, this ”sandwich” approach for patients with endometrial cancer has been studied recently. Several authors have reported that treatment modality is associated with a low rate of local recurrence and favorable survival for advanced endometrial cancer.